Ciprofloxacin Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Ciprofloxacin Hydrochloride
- Ciprofloxacin Hydrochloride: Repurposing Analysis Unavailable — Data Gaps Prevent Evaluation
Ciprofloxacin Hydrochloride: Repurposing Analysis Unavailable — Data Gaps Prevent Evaluation
One-Sentence Summary
Ciprofloxacin Hydrochloride is a broad-spectrum fluoroquinolone antibiotic widely used for bacterial infections including urinary tract infections, respiratory tract infections, and skin and soft tissue infections. No TxGNN repurposing predictions were generated for this drug in the current evidence pack, as critical inputs — including the DrugBank ID, mechanism of action, and original indication mapping — were not resolved. A meaningful drug repurposing evaluation cannot be completed until these data gaps are remediated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (broad-spectrum antibiotic; data not formally mapped in this pack) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — model prediction not generated; no supporting studies retrievable |
| South Africa Market Status | Not registered (no SAHPRA licences found) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why No Predictions Were Generated
The TxGNN pipeline requires a confirmed DrugBank ID to anchor the drug within the knowledge graph and generate repurposing candidates. Although the DrugBank query returned one result (result_status: success, result_count: 1), the DrugBank ID field was not populated in the processed output and no original indications were mapped. Without this anchor, the knowledge graph traversal and deep-learning scoring steps cannot run.
Ciprofloxacin Hydrochloride is a well-characterised fluoroquinolone antibiotic. Its mechanism centres on inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication and repair in bacteria. These targets have attracted research interest beyond antibacterial use — notably in oncology (gyrase-like topoisomerases in cancer cells) and inflammatory conditions — meaning that once DrugBank linkage is restored, TxGNN may generate meaningful repurposing candidates.
The absence of SAHPRA registration data is also unexpected: ciprofloxacin formulations are in widespread clinical use across South Africa. This is most likely a data-extraction failure rather than a genuine absence of registration, and should be verified against the SAHPRA online register before any regulatory conclusions are drawn.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information. Report adverse drug reactions to SAHPRA via the MedSafety online reporting portal.
Note: Key warnings, contraindications, and drug–drug interaction data were all flagged as unavailable in this evidence pack. Two data gaps were formally recorded:
- DG001 (Blocking): SAHPRA PI warnings and contraindications not retrieved — prevents safety pre-screening.
- DG002 (High): Mechanism of action not retrieved from DrugBank — prevents mechanistic plausibility analysis.
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing predictions were generated because the DrugBank ID linkage failed downstream of a successful API query, leaving the TxGNN knowledge graph without an entry point for this drug. Proceeding without predictions or safety data would not be clinically meaningful.
To proceed, the following is needed:
- Resolve DrugBank ID: The DrugBank query succeeded but the ID was not written to the evidence pack. Confirm the correct identifier (expected: DB00537) and re-run the mapping step.
- Re-run TxGNN predictions: Once the DrugBank ID is confirmed, re-execute the knowledge graph and deep-learning prediction pipelines to generate scored repurposing candidates.
- Retrieve SAHPRA PI (DG001 — Blocking): Download and parse the SAHPRA-approved Professional Information PDF to extract warnings, contraindications, and approved indications; this is required before any safety pre-screening can proceed.
- Retrieve MOA from DrugBank (DG002 — High): Query the DrugBank API for mechanism of action, pharmacodynamics, and target data to enable mechanistic plausibility analysis.
- Verify SAHPRA registration status: Cross-check the SAHPRA online medicines register directly, as the zero-registration result is inconsistent with the drug’s known availability in South Africa.
This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Data cutoff: 2026-04-05.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.